Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharmaceutical Industries, a specialty pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application for generic Sinemet CR, an extended release version of carbidopa with levodopa.
Subscribe to our email newsletter
Carbidopa with levodopa extended release is indicated for the treatment of Parkinson’s disease and syndrome.
These generic extended release versions of carbidopa with levodopa are bio-equivalent to Sinemet CR marketed by Bristol-Myers and Squibb Company and will be available as tablets in two strengths: 25mg carbidopa with 100mg levodopa and 50mg carbidopa with 200mg levodopa. The company expects to reach the market shortly with these products.